Loading...

PE Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Phycoerythrin, SAv-PE
Ave. Rating
Submit a Review
Product Citations
publications
SAV_PE_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
  • SAV_PE_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
405204 500 µg NOK1609
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405203 100 µg NOK462
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.

Application References
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. He X, et al. 2014. J Immunol. 193:1314. PubMed
  18. Wang W, et al. 2014. PNAS. 111:14466. PubMed
  19. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  20. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  21. Kim Yu, et al. 2015. PLoS One. 10:120294. PubMed
  22. Hua X, et al. 2015. PloS One. 10:128039. PubMed
Product Citations
  1. Martínez-Blanco Á, et al. 2021. Front Immunol. 12:713697. PubMed
  2. Wu Y, et al. 2021. Immunity. 54:2595. PubMed
  3. Goel RR, et al. 2022. Cell. 185:1875. PubMed
  4. Campisi L, et al. 2022. Nature. 606:945. PubMed
  5. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  6. Wu Y, et al. 2022. Sci Adv. 8:eabm7833. PubMed
  7. Cao Y, et al. 2023. Nature. 614:521. PubMed
  8. Weskamm LM, et al. 2022. STAR Protoc. 3:101902. PubMed
  9. Mekkaoui L, et al. 2023. Mol Ther Methods Clin Dev. 28:116. PubMed
  10. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  11. Hernandez SPA, et al. 2023. Front Immunol. 13:1035344. PubMed
  12. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  13. Knyphausen P, et al. 2023. Nat Commun. 14:768. PubMed
  14. Yeh CH, et al. 2022. Immunity. 55:272. PubMed
  15. Feng J, et al. 2022. Immunity. 55:405. PubMed
  16. Zhang Y, et al. 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. PubMed
  17. Wang H, et al. 2020. Mol Oncol. 14:991. PubMed
  18. Eger C, et al. 2016. PLoS One. 11: 0150479. PubMed
  19. Yang J, et al. 2016. Sci Rep. 6:38238. PubMed
  20. Chen T, et al. 2016. J Exp Med. 13(13):3025-3039. PubMed
  21. Tas JMJ, et al. 2022. Immunity. 55:1856. PubMed
  22. Melzi E, et al. 2022. Immunity. 55:2168. PubMed
  23. Vyasamneni R, et al. 2023. Cell Rep Methods. 3:100388. PubMed
  24. Ke F, et al. 2023. Elife. 12:. PubMed
  25. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  26. Silva RP, et al. 2023. Elife. 12:. PubMed
  27. Nozuma S, et al. 2023. JCI Insight. 8:. PubMed
  28. García-Vega M, et al. 2023. iScience. 26:106562. PubMed
  29. Liu Y, et al. 2023. Nat Commun. 14:2179. PubMed
  30. Fathi M, et al. 2023. iScience. 26:106482. PubMed
  31. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  32. Lv X, et al. 2023. Acta Pharm Sin B. 13:1631. PubMed
  33. Li X, et al. 2023. Nat Commun. 14:2929. PubMed
  34. Tundidor I, et al. 2023. Nat Commun. 14:3130. PubMed
  35. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  36. Golubovskaya V, et al. 2023. Cancers (Basel). 15:. PubMed
  37. Feng, D., Guo, J., et al. 2025. Microbiol Spectr. 13(10),e0136225. PubMed
  38. Lv X, et al. 2022. Acta Pharm Sin B. 12:735. PubMed
  39. Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
  40. Tian L, et al. 2021. Int J Mol Sci. 22: . PubMed
  41. Trendel N, et al. 2021. Sci Signal. 14:eaay9363. PubMed
  42. Gatineau J, et al. 2022. Front Immunol. 13:982839. PubMed
  43. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  44. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  45. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  46. Grevers L, et al. 2013. Ann Rheum Dis. 72:278. PubMed
  47. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  48. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  49. Hernandez-Franco JF, et al. 2022. Front Immunol. 13:990900. PubMed
  50. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  51. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  52. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  53. Biswas S, et al. 2021. Nature. 591:464. PubMed
  54. Wellner A, et al. 2021. Nat Chem Biol. 17:1057. PubMed
  55. Ruiz–Camp J, et al. 2019. EMBO Mol Med. 11:3. PubMed
  56. Nie X, et al. 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. PubMed
  57. Gniffke EP, et al. 2020. medRxiv. . PubMed
  58. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  59. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  60. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  61. Ashbaugh J, et al. 2013. J Immunol. 190:4525. PubMed
  62. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  63. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  64. Cao Y, et al. 2022. Nature. :. PubMed
  65. He X, et al. 2021. Emerg Microbes Infect. 10:1555. PubMed
  66. Nishimoto K, et al. 2008. J Immunol. 181:4010. PubMed
  67. Im S, et al. 2016. Nature. 537:417-421. PubMed
  68. Schanda N, et al. 2021. Cells. 10:. PubMed
  69. Tsukamoto H, et al. 2013. Biochem Biophys Res Commun. 440:31. PubMed
  70. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  71. Weiß S, et al. 2020. J Infect Dis. 222:1629. PubMed
  72. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  73. Kristensen NP, et al. 2022. J Clin Invest. 132:. PubMed
  74. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  75. Cao Y, et al. 2022. Nature. 602:657. PubMed
  76. Rogers BM, et al. 2021. J Exp Med. 218:. PubMed
  77. Niki T, et al. 2009. J Biol Chem. 284:32344. PubMed
  78. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  79. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  80. Köchl R, et al. 2020. Elife. 9:00. PubMed
  81. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  82. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  83. Mei H, et al. 2021. J Hematol Oncol. 14:161. PubMed
  84. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  85. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  86. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  87. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  88. Reading J, et al. 2013. J Immunol. 190:4542. PubMed
  89. Weiß S, et al. 2020. medRxiv. . PubMed
  90. Hebbar N, et al. 2022. Nat Commun. 13:587. PubMed
  91. Tschismarov R, et al. 2021. JCI Insight. 6:. PubMed
  92. Richardson LS, et al. 2020. Lab Chip. 3.948611111. PubMed
  93. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  94. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  95. McWilliam H, et al. 2016. Nat Immunol. 17: 531-537. PubMed
  96. Zhang S, et al. 2016. Sci Transl Med. 8: 341ra77. PubMed
  97. Parente-Pereira AC, et al. 2022. STAR Protoc. 3:101319. PubMed
  98. Baltierra-Uribe SL, et al. 2021. Eur J Immunol. 51:2641. PubMed
  99. Schoutrop E, et al. 2022. Oncoimmunology. 11:2093426. PubMed
  100. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  101. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  102. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  103. Mainini F, et al. 2015. PLoS One. 10: 0145403. PubMed
  104. Woo S, et al. 2013. J Leukoc Biol. 93:363. PubMed
  105. Baccala R, et al. 2012. J Immunol. 189:5976. PubMed
  106. Guo C, et al. 2021. Cell Rep Med. 2:100448. PubMed
  107. Chen YL, et al. 2021. J Biol Chem. :101420. PubMed
  108. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  109. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  110. Tian B, et al. 2017. Front Immunol. 10.3389/fimmu.2017.00956. PubMed
  111. Schoofs T et al. 2019. Immunity. 50(6):1513-1529 . PubMed
  112. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  113. Scatizzi J, et al. 2012. J Immunol. 188:3307. PubMed
  114. Günaydın G, et al. 2014. Vaccine. 32:470. PubMed
  115. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  116. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  117. Roewe J, et al. 2020. Nat Commun. 3.260416667. PubMed
  118. Matsuda T, et al. 2022. iScience. 25:105324. PubMed
  119. Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed
  120. Cheloha RW, et al. 2021. RSC chem biol. 2:1692. PubMed
  121. Okamoto Y, et al. 2021. J Cell Sci. 134:. PubMed
  122. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  123. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  124. Gniffke EP, et al. 2020. J Infect Dis. 222:1965. PubMed
  125. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  126. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  127. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  128. Lu X, et al. 2019. Cell Rep. 28:472. PubMed
  129. Wang W, et al. 2014. Proc Natl Acad Sci U S A. 111:14466. PubMed
  130. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  131. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  132. Dan JM, et al. 2021. Science. :371. PubMed
  133. He X, et al. 2014. J Immunol. 193:1314. PubMed
  134. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  135. Walker MR, et al. 2022. Sci Adv. 8:eabj9513. PubMed
  136. Yang Zhou J, et al. 2022. Front Immunol. 13:898473. PubMed
  137. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  138. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  139. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  140. Wang EY, et al. 2022. Cell Rep Methods. 2:. PubMed
  141. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  142. Wells DK, et al. 2020. Cell. 183:818. PubMed
  143. Chappaz S, et al. 2010. J Immunol. 185:3514. PubMed
  144. Altman JB, et al. 2018. Health Sci Rep. 1:e74. PubMed
  145. Hirunwidchayarat W, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. PubMed
  146. Schürch CM, et al. 2020. Cell. 182:1341. PubMed
  147. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. PubMed
  148. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  149. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  150. Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
  151. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  152. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  153. Yang C, et al. 2019. Nat Commun. 10:3931. PubMed
  154. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  155. Tripathi S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. PubMed
  156. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. PubMed
  157. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  158. Holm JS, et al. 2022. Nat Commun. 13:1935. PubMed
  159. Lautz JD, et al. 2019. Sci Rep. 9:10890. PubMed
  160. Kenney M, et al. 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. PubMed
  161. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  162. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed
  163. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 6    Revision Date: 06.17.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account